Schedule of parent company financial statements |
ASSETS |
|
March
31, 2021
|
|
|
December
31,
2020
|
|
Current Assets: |
|
|
|
|
|
|
Cash
and cash equivalents |
|
$ |
16,534 |
|
|
$ |
25,632 |
|
Receivables
from subsidiaries |
|
|
16,412 |
|
|
|
15,548 |
|
Other
current assets |
|
|
2,188 |
|
|
|
1,836 |
|
Total
current assets |
|
|
35,134 |
|
|
|
43,016 |
|
|
|
|
|
|
|
|
|
|
Property
and equipment, net |
|
|
125 |
|
|
|
142 |
|
Other Assets: |
|
|
|
|
|
|
|
|
Investments
in subsidiaries |
|
|
257,547 |
|
|
|
246,518 |
|
Alto West,
LLC receivable |
|
|
42,649 |
|
|
|
42,649 |
|
Right of
use operating lease assets, net |
|
|
2,915 |
|
|
|
2,985 |
|
Other
assets |
|
|
1,087 |
|
|
|
1,088 |
|
Total
other assets |
|
|
304,198 |
|
|
|
293,240 |
|
Total
Assets |
|
$ |
339,457 |
|
|
$ |
336,398 |
|
Current
Liabilities: |
|
|
|
|
|
|
|
|
Accounts
payable and accrued liabilities |
|
$ |
4,961 |
|
|
$ |
2,001 |
|
Accrued
Alto Op Co. purchase |
|
|
3,829 |
|
|
|
3,829 |
|
Current
portion of long-term debt |
|
|
20,001 |
|
|
|
25,533 |
|
Other
current liabilities |
|
|
394 |
|
|
|
473 |
|
Total
current liabilities |
|
|
29,185 |
|
|
|
31,836 |
|
|
|
|
|
|
|
|
|
|
Long-term
debt, net of current portion |
|
|
5,665 |
|
|
|
5,564 |
|
Other
liabilities |
|
|
2,925 |
|
|
|
2,763 |
|
Total
Liabilities |
|
|
37,775 |
|
|
|
40,163 |
|
Stockholders’
Equity: |
|
|
|
|
|
|
|
|
Preferred
stock |
|
|
1 |
|
|
|
1 |
|
Common
and non-voting common stock |
|
|
73 |
|
|
|
72 |
|
Additional
paid-in capital |
|
|
1,037,718 |
|
|
|
1,036,638 |
|
Accumulated
other comprehensive loss |
|
|
(3,878 |
) |
|
|
(3,878 |
) |
Accumulated
deficit |
|
|
(732,232 |
) |
|
|
(736,598 |
) |
Total
Alto Ingredients, Inc. stockholders’ equity |
|
|
301,682 |
|
|
|
296,235 |
|
Total
Liabilities and Stockholders’ Equity |
|
$ |
339,457 |
|
|
$ |
336,398 |
|
|
Schedule of statement of operations parent company |
|
|
Three Months Ended
March 31,
|
|
|
|
2021
|
|
|
2020
|
|
Management fees from subsidiaries |
|
$ |
2,526 |
|
|
$ |
3,253 |
|
Selling, general and administrative expenses |
|
|
4,651 |
|
|
|
5,377 |
|
Loss from operations |
|
|
(2,125 |
) |
|
|
(2,124 |
) |
Fair value adjustments |
|
|
— |
|
|
|
673 |
|
Interest expense, net |
|
|
(1,028 |
) |
|
|
(1,598 |
) |
Other income |
|
|
807 |
|
|
|
— |
|
Loss before benefit for income taxes |
|
|
(2,346 |
) |
|
|
(3,049 |
) |
Benefit for income taxes |
|
|
— |
|
|
|
— |
|
Loss before equity in losses of subsidiaries |
|
|
(2,346 |
) |
|
|
(3,049 |
) |
Equity in income (losses) of subsidiaries |
|
|
7,024 |
|
|
|
(24,107 |
) |
Consolidated net income (loss) |
|
$ |
4,678 |
|
|
$ |
(27,156 |
) |
|
Schedule of statement of cash flows parent company |
|
|
For
the Three Months Ended
March 31, |
|
|
|
2021 |
|
|
2020 |
|
Operating Activities: |
|
|
|
|
|
|
Consolidated
net income (loss) |
|
$ |
4,678 |
|
|
$ |
(27,156 |
) |
Adjustments
to reconcile net income (loss) to cash used in operating activities: |
|
|
|
|
|
|
|
|
Equity
in (income) losses of subsidiaries |
|
|
(7,024 |
) |
|
|
24,107 |
|
Fair value adjustments |
|
|
— |
|
|
|
(673 |
) |
Depreciation |
|
|
17 |
|
|
|
33 |
|
Amortization
(accretion) of debt discount (premium) |
|
|
101 |
|
|
|
(57 |
) |
Changes
in operating assets and liabilities: |
|
|
|
|
|
|
|
|
Receivables
from subsidiaries |
|
|
(864 |
) |
|
|
123 |
|
Other
assets |
|
|
(281 |
) |
|
|
29 |
|
Accounts
payable and accrued expenses |
|
|
(765 |
) |
|
|
— |
|
Accounts
payable with subsidiaries |
|
|
110 |
|
|
|
2,235 |
|
Net
cash used in operating activities |
|
$ |
(4,028 |
) |
|
$ |
(1,359 |
) |
Investing
Activities: |
|
|
|
|
|
|
|
|
Additions
to property and equipment |
|
$ |
— |
|
|
$ |
— |
|
Net
cash used in investing activities |
|
$ |
— |
|
|
$ |
— |
|
Financing
Activities: |
|
|
|
|
|
|
|
|
Proceeds
from issuances of common stock |
|
$ |
462 |
|
|
$ |
282 |
|
Proceeds
from plant receivable |
|
|
— |
|
|
|
5,813 |
|
Payments
on senior notes |
|
|
(5,532 |
) |
|
|
— |
|
Preferred
stock dividend payments |
|
|
— |
|
|
|
— |
|
Net
cash provided by (used in) financing activities |
|
$ |
(5,070 |
) |
|
$ |
6,095 |
|
Net increase (decrease) in
cash and cash equivalents |
|
|
(9,098 |
) |
|
|
4,736 |
|
Cash
and cash equivalents at beginning of period |
|
|
25,632 |
|
|
|
4,985 |
|
Cash
and cash equivalents at end of period |
|
$ |
16,534 |
|
|
$ |
9,721 |
|
|